Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oryzon GenomicsORYZF 33 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates ORYZF with a GF Score™ of 33/100. Among 965 Biotechnology companies, Oryzon Genomics ranks better than 65.7% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Oryzon Genomics's Debt-to-Equity or its related term are showing as below:
ORYZF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.19 Max: 0.87
Current: 0.07
During the past 12 years, the highest Debt-to-Equity Ratio of Oryzon Genomics was 0.87. The lowest was 0.00. And the median was 0.19.
ORYZF's Debt-to-Equity is ranked better than 65.7% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs ORYZF: 0.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Oryzon Genomics Debt-to-Equity Related Terms
Oryzon Genomics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Oryzon Genomics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORYZF vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Oryzon Genomics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oryzon Genomics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oryzon Genomics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Oryzon Genomics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oryzon Genomics (ORYZF) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Oryzon Genomics and its competitors. According to the industry distribution chart, Oryzon Genomics ranks #331 out of 965 companies in the Biotechnology industry, placing it in the top 34.3%.
Is Oryzon Genomics' Debt-to-Equity too high?
Oryzon Genomics' current Debt-to-Equity is 0.00. Based on the distribution chart, Oryzon Genomics ranks #331 out of 965 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oryzon Genomics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oryzon Genomics ranks #331 out of 965 companies for Debt-to-Equity. This puts Oryzon Genomics in the upper half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Oryzon Genomics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oryzon Genomics's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (ORYZF) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Oryzon Genomics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Oryzon Genomics (ORYZF), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
33GF Score
Get the complete analysis for ORYZF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORYZF has been successfully added to your 
